The global pharmaceutical industry experienced a 13% drop in company filings mentions of environmental sustainability in Q3 2023 compared with the previous quarter, with the highest share accounted for by Merck with 71% year-on-year increase, according to GlobalDataâ€™s analysis of over 588 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, environmental sustainability was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of niche tourism and blockchain, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Merck had the greatest increase in references for environmental sustainability in Q3 2023, compared with the previous quarter. GlobalData identified 694 environmental sustainability-related sentences in the company's filings - 14% of all sentences - and an increase of 71% in Q3 2023 compared with Q3 2022. Samsung Biologicsâ€™s mentions of environmental sustainability rose by 3363% to 277 and Bristol-Myers Squibbâ€™s by 11700% to 236 and Dr. Reddy's Laboratoriesâ€™s by 469% to 222 and Sun Pharmaceutical Industriesâ€™s by 67% to 174.
GlobalDataâ€™s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for environmental sustainability in Q3 2023 was 149.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.